Personalis reported third quarter 2026 sales of US$25.6 million and a net loss of US$33.8 million, with basic loss per share from continuing operations of US$0.32. For the nine month period, the company reported sales of US$63.43 million and a net loss of US$95.52 million, or US$0.90 per share. The earnings update showed higher top line figures alongside wider losses, which highlights ongoing cost intensity and execution pressure as Personalis scales its cancer genomics business. We will...
FREMONT, Calif., October 21, 2026--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that two oral presentations and two poster presentations featuring its NeXT Personal ultrasensitive circulating tumor DNA (ctDNA) test will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. Highlights include a late-breaking oral presentation of NeXT Personal data for the C-POST Phase 3
Cathie Wood’s Ark Invest addedto its positions in AI infrastructure and social media companies, buying $25.9M of CoreWeave (CRWV) and $24.4M of Meta Platforms (META). It also purchased $16.3M of Cerebras Systems (CBRS) and $9.4M of Rocket Lab (RKLB)
Personalis shareholders remain exposed to downside in TEM shares while having limited ability to benefit from further TEM appreciation above $48.42. Learn more about PSNL stock here.
Tempus AI, Inc. (NASDAQ:TEM) rallied following a melanoma breakthrough reported by Moderna and Merck. The companies said their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for the personalized cancer therapy intismeran autogene, also known as V940, combined with Keytruda. Detailed trial data remain pending. The read-through came from Personalis, which has supported the […]
Personalis (PSNL) has demonstrated exceptional momentum, gaining nearly 250% over the past year. Shares recently set a new 3-year high. PSNL stock maintains a 100% “Buy” technical opinion from Barchart. Despite strong price appreciation, PSNL remains unprofitable and highly speculative, with mixed analyst sentiment and significant short interest. Today’s Featured...
Tempus AI, Inc. made a timely move to acquire the Personalis cancer monitoring tests to advance AI-driven precision medicine. Learn why TEM stock is a strong buy.
In recent days, investors have reacted to phase 3 INTerpath-001 trial results showing a customized mRNA-based melanoma treatment improved recurrence-free survival, while also focusing on Tempus AI’s pending US$1.50 billion acquisition of Personalis Inc. as a move deeper into cancer genomics. Together, the trial success and acquisition plan highlight how Tempus AI is tying advanced mRNA oncology research to its broader precision medicine and data-driven cancer testing ambitions. We’ll now...
This is the newest page. Registered accounts read further back.